Match tier Likely match
Presence Current · Arkansas
Last published 2025
Sources OpenAlex · ORCID
Refreshed 2026-08-15

Beverly Lyn‐Cook

This is a likely match — the affiliation was inferred from OpenAlex, ORCID, and web sources but has not been fully confirmed. Treat with appropriate caution.

High Impact

Researcher

Also affiliated: University of North Carolina at Chapel Hill (1983–2008); North Carolina Central University (2004); U.S. National Science Foundation (2006); United States Food and Drug Administration (2008–2025); Missouri Department of Agriculture (2018); Office of Multidisciplinary Activities (2013); Beverly Hospital (2015); Clark Atlanta University (1984); Canisius College (1992); Western University of Health Sciences (2008)

Faculty Researcher

30 h-index 130 pubs 3,166 cited

  • Humans
  • Female
  • Animals
  • Male
  • Rats
  • Gene Expression
  • White People
  • Middle Aged
  • Pancreatic Neoplasms
  • Gene Expression Regulation, Neoplastic
  • Adult
  • Cell Line, Tumor
  • Cells, Cultured
  • RNA, Messenger
  • Black or African American

Biography and Research Information

OverviewAI-generated summary

Beverly Lyn‐Cook's research focuses on understanding disease mechanisms and health disparities, particularly concerning cancer, metabolism, and the impact of environmental exposures. Her work frequently investigates differences across demographic groups, including sex and race, and utilizes advanced computational methods for data analysis. Lyn‐Cook has published on topics such as the metabolome of breast tissues and its correlation with microbial dysbiosis and lipid metabolism in triple-negative breast tumors, and the association of tryptophan metabolism with obesity and triple-negative breast cancer risk in Black and White women.

Her research also explores the immunotoxicity of nanoparticles, examining sex-based differences in response to agents like silver nanoparticles. Additionally, she has investigated the effects of nanoparticles, such as titanium dioxide, on epigenetic modifications in human cell lines. Lyn‐Cook employs sophisticated data mining and topic modeling techniques, including AI-powered approaches like LDA and BERTopic, to analyze large datasets, such as those related to opioid adverse events and prescription opioid use literature.

Lyn‐Cook is a highly cited researcher with an h-index of 30 and over 130 publications. She leads a research group and has collaborated extensively with colleagues at the National Center for Toxicological Research, including Beverly Word, Paul Rogers, Wen Zou, and Weigong Ge.

Metrics

  • h-index: 30
  • Publications: 130
  • Citations: 3,166

Selected Publications

  • Abstract C054: Pharmacogenomics evaluation of histone deacetylase inhibitors on the treatment of triple-negative breast cancer subtypes (2025)
    Cancer Epidemiology Biomarkers & Prevention DOI OpenAlex
  • AI-powered topic modeling: comparing LDA and BERTopic in analyzing opioid-related cardiovascular risks in women (2025)
    Experimental Biology and Medicine 49 citations DOI OpenAlex
  • Exposure to a Titanium Dioxide Product Alters DNA Methylation in Human Cells (2024)
    Nanomaterials 2 citations DOI OpenAlex
  • Identifying Vulnerabilities to NSAID Adverse Events in the U.S. Population: An Analysis of Preexisting Conditions and Sex (2024)
    Journal of Women s Health DOI OpenAlex
  • Abstract 4253: High expression of specific gene profiles in organoids from African American pancreatic cancer tumors (2024)
    Cancer Research DOI OpenAlex
  • Investigation of sex-based differences in the immunotoxicity of silver nanoparticles (2024)
    Nanotoxicology 10 citations DOI OpenAlex
  • RxNorm for drug name normalization: a case study of prescription opioids in the FDA adverse events reporting system (2024)
    Frontiers in Bioinformatics 9 citations DOI OpenAlex
  • A systematic analysis and data mining of opioid-related adverse events submitted to the FAERS database (2023)
    Experimental Biology and Medicine 7 citations DOI OpenAlex
  • Identifying Vulnerabilities to NSAID Adverse Events in the US Population: An Analysis of Pre-Existing Conditions and Sex (2023)
  • Epigenotoxicity of Titanium Dioxide Nanoparticles (2023)
    3 citations DOI OpenAlex
  • Abstract 6251: High expression level of GSK3β in basal triple negative breast cancer: Effects of the HDAC inhibitor, vorinostat (2023)
    Cancer Research DOI OpenAlex
  • Characterization of the Metabolome of Breast Tissues from Non-Hispanic Black and Non-Hispanic White Women Reveals Correlations between Microbial Dysbiosis and Enhanced Lipid Metabolism Pathways in Triple-Negative Breast Tumors (2022)
    Cancers 12 citations DOI OpenAlex
  • Effect of titanium dioxide nanoparticles on histone modifications and histone modifying enzymes expression in human cell lines (2022)
    Nanotoxicology 9 citations DOI OpenAlex
  • Abstract 1631: Anti-cancer effects of vorinostat on 3D cultured pancreatic cancer cells (2022)
    Cancer Research 1 citation DOI OpenAlex
  • Abstract 3022: Tryptophan metabolism is associated with obesity and triple negative breast cancer risk in black and white women (2022)
    Cancer Research 3 citations DOI OpenAlex

View all publications on OpenAlex →

Collaboration Network

40 Collaborators 9 Institutions 3 Countries

Top Collaborators

View profile →
View profile →
View profile →
View profile →
View profile →
View profile →
View profile →

Similar Researchers

Based on overlapping research topics